A significant antifibrotic effect was also reported for the antidiabetic agent metformin which was demonstrated to inhibit TGF-β1-induced fibrosis and myofibroblast differentiation in different fibrotic models including experimental scleroderma [121], and the two tyrosine kinase inhibitors nilotinib and imatinib, which are both able to target PDGFR and c-Abl, the latter being one of the key non-receptor tyrosine kinases mediating not only the non-canonical TGF-β pathway, but also VEGFR and FGFR signaling [43,117,122]. The gene discussed is TGFB1; the disease is scleroderma.